Bank of Montreal
RGLS

Bank of Montreal’s Regulus Therapeutics RGLS Stock Holding History

Bank of Montreal’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-38
Closed -$3K – 4841
2018
Q1 		$3K Buy
+38
New +$5.08K ﹤0.01% 4003
2017
Q4 		– Hold
0
– – – 4299
2017
Q3 		– Hold
0
– – – 4297
2017
Q2 		– Hold
0
– – – 4263
2017
Q1 		– Hold
0
– – – 4157
2016
Q4 		– Hold
0
– – – 4164
2016
Q3 		– Hold
0
– – – 4163
2016
Q2 		– Sell
-1
Closed – – 4279
2016
Q1 		$0 Hold
1
– – ﹤0.01% 4369
2015
Q4 		$1K Hold
1
– – ﹤0.01% 4104
2015
Q3 		$0 Hold
1
– – ﹤0.01% 4125
2015
Q2 		$1K Hold
1
– – ﹤0.01% 3850
2015
Q1 		$1K Hold
1
– – ﹤0.01% 3869
2014
Q4 		$3K Buy
+1
New +$1.78K ﹤0.01% 3786
2014
Q3 		– Sell
-2
Closed -$2K – 4347
2014
Q2 		$2K Buy
+2
New +$1.71K ﹤0.01% 4510

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.36% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Bank of Montreal's RGLS Position: Q2 2018 in Review

Bank of Montreal sold out of Regulus Therapeutics (RGLS) in Q2 2018, closing a stake of 38 shares — an estimated $3K sold.

Bank of Montreal first reported a position in RGLS in Q2 2014 and held it in 8 quarters. The position peaked at $3K in Q1 2018. 46 funds tracked by Wall St. Rank hold RGLS as of Q2 2018.

  • Bank of Montreal reported no remaining Regulus Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Bank of Montreal sold 38 Regulus Therapeutics shares in Q2 2018, an estimated $3K.
  • Bank of Montreal first reported a position in Regulus Therapeutics in Q2 2014 and held it in 8 quarters.
  • Bank of Montreal's Regulus Therapeutics position peaked at $3K in Q1 2018.
  • 46 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2018.

Based on Bank of Montreal's 13F filing for Q2 2018, filed 16 Jul 2018.